Tag: CPAP Alternative
No silver bullet, no problem: Daybreak bets on more options for sleep apnea
June 26, 2026Theresa Flaherty
LOS ANGELES – Daybreak has paired a new awareness campaign – aimed at making March Sleep Apnea Awareness Month across multiple states – with increased hiring and channel expansion, underscoring its push to reach millions of undiagnosed patients.
“We’re at a point where we can start changing how people think about sleep apnea – its severity and how it’s treated,” said CEO Wesley Lones. “There’s no silver bullet. Different treatments work...
New therapies challenge CPAP, but providers aren’t shifting yet
June 19, 2026Liz Beaulieu, Editor
YARMOUTH, Maine – There may be an increasing number of options to treat obstructive sleep apnea (OSA), but CPAP remains the top choice, say 68% of respondents to a recent HME Newspoll.
“The sleep apnea treatment landscape is becoming increasingly diverse, which is good news for patients,” wrote one respondent. “New options, such as oral appliances, implantable devices and emerging medications may help people who struggle with CPAP therapy. That said, CPAP remains the gold...
ProSomnus, MonitAir collaborate to facilitate clinical visibility into OSA
June 16, 2026HME News Staff
SAN FRANCISCO – ProSomnus Sleep Technologies and MonitAir, a digital health and telemonitoring platform for sleep medicine, have collaborated to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ OSA Device will be able to view, organize and remotely monitor patient data within the MonitAir platform. The companies say the integration is intended to facilitate...
Apnimed backs OSA pill with two new peer-reviewed articles
May 19, 2026HME News Staff
CAMBRIDGE, Mass. – Apnimed has published two peer-reviewed articles on AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg), an investigational, once-daily oral pill taken at bedtime designed to improve oxygenation and target the neuromuscular root cause of obstructive sleep apnea (OSA). The Phase 3 SynAIRgy trial results are published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), alongside a companion mechanistic review article in the American Journal of Respiratory...
ProSomnus: ‘We are enabling smart sleep medicine’
April 14, 2026HME News Staff
SAN FRANCISCO – ProSomnus Sleep Technologies has announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂ OSA Device under the product codes DQA, LQZ, LRK, PLC, and OUG (FDA K252765). The company says the RPMO2 OSA Device is the first theranostic device for sleep medicine, incorporating both precision oral appliance therapy and multi-night physiologic monitoring in one device. With this new clearance, it says the device is positioned as...
Apnimed secures $150M in debt financing ahead of planned launch of pill to treat OSA
April 7, 2026HME News Staff
CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company developing oral therapies for obstructive sleep apnea (OSA), has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners (HCRx). The company plans to use the capital to support commercial readiness activities and the planned U.S. launch of its lead product candidate, AD109, if approved by the U.S. Food and Drug Administration (FDA). "HCR is a highly respected health care...
LivaNova receives FDA premarket approval for CPAP alternative
March 23, 2026HME News Staff
LONDON – LivaNova has announced that the U.S. Food & Drug Administration (FDA) has granted premarket approval (PMA) for the aura6000 System for the treatment of adult patients with moderate to severe obstructive sleep apnea (OSA). The system uses proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with an apnea-hypopnea index (AHI) between 15 and 65 and who have failed, do not tolerate or are ineligible for first-line therapies,...
ProSomnus receives $38M investment to grow in alternative sleep market
February 18, 2026HME News Staff
SAN FRANCISCO – ProSomnus has raised $38 million through a strategic investment from Catalio Capital Management to accelerate the expansion of its sleep health platform, according to a report from MassDevice.com.
ProSomnus develops non-CPAP obstructive sleep apnea (OSA) therapy offerings. With the investment, it plans to advance the development of next-generation remote patient monitoring and proprietary sleep diagnostic devices. It hopes to...
New study backs virtual treatment pathway for CPAP alternative
January 12, 2026HME News Staff
LOS ANGELES – A new Cedars Sinai Physician Associated Study used the processes and care of Daybreak to evaluate a dentist-led, telehealth-guided treatment pathway that includes remote sleep testing, guided at-home capture of dental impressions, ongoing virtual titration, and follow-up. Researchers found the clinical outcomes were comparable to, or better than, traditional in-clinic mandibular advancement device studies, demonstrating effective...
Robert Miller leads Daybreak’s push for CPAP alternatives
January 2, 2026Theresa Flaherty
YARMOUTH, Maine – There’s a new landscape of available sleep apnea treatments, something that Robert Miller, an RSPGT, has seen evolve over his long career, which has included leading roles at major sleep players, including MedBridge Healthcare and, most recently, Apria Healthcare.
Miller is now senior vice president of commercial strategy for Daybreak, a provider of at-home sleep testing and care,...